Sign in with Google
bullish
Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q2
328 Views24 Oct 2024 14:21
SUMMARY
- Dr Lal PathLabs Ltd (DLPL IN) reported 10% revenue growth in Q2, driven by volume. The bottomline surge of 18% has again outpaced revenue growth, resulting in margin expansion.
- There has been a significant improvement in Suburban’s revenue growth rate at 12%, with EBITDA margin reaching 20%. The company maintained 10% revenue growth target for the current financial year.
- The operating environment is becoming conducive. Competitive intensity in terms of predatory pricing, promotional offer, and cash burning to acquire customers, have come to an end.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Northern Star's Acquisition of De Grey Mining: The Many Index Implications & Flows
- Tariff Transition Smoothing
- Shin Kong (2888 TT)/Taishin (2887 TT) Deal Gets FSC Approval - Still A Good Swap
- Quiddity Leaderboard T50/100 Jun25: Taishin-Shin Kong Merger Could Cause Two Changes
- BYD (1211 HK) Tactical Outlook: Buy-The-Dip Scenarios With Passive Buying from HSI/HSCEI Trackers
Top Unpaywalled Insights
More »- The Toyota Way Is Not to Rush, but to Gain a Foothold and Proceed with Caution
- [IO Technicals Weekly 2025/13]: Bullish Momentum Builds as IV Eases
- Aiming for REITs with Lower Downside Risk and Expectations of Higher Shareholder Returns?
- Tariffs, Tapering, and Tectonic Shifts: Markets Brace for April | The New Barbarians #013
- APL Apollo Tubes (APAT IN) Stepping up the Gas on Capacity Expansions
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q224 Oct 2024
- Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition02 Oct 2024
- Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook11 Jul 2023
- Dr Lal PathLabs (DLPL IN): Losing Path Amid Competition; Non-COVID Growth Underwhelming30 Mar 2023
x